Qiong He

Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib

Chen Lin, Xin-min Yu, Junrong Yan, 2022, BMC cancer.

Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation

P. A. Futreal, I. Wistuba, Yamei Chen, 2019, Oncogene.

Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer

Y. Shao, Jun Zhao, Ying-yu Jin, 2020, Frontiers in Oncology.

Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.

Jun Zhao, Chen Lin, Xin-min Yu, 2019, Lung cancer.

Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas.

Xue Wu, Y. Shao, Q. Ou, 2018, Lung cancer.

cfDNA changes for monitoring of targeted therapy in a primary EGFR mutation lung adenocarcinoma

Xun Shi, Xian Zhu, Chen Lin, 2020, Translational lung cancer research.